Psychedelic drug MDMA faces FDA panel in bid to become first-of-a-kind PTSD medication

In this photo made with a long exposure, a man is silhouetted against lights reflected in the waters off Cape Neddick in Maine on Dec. 11, 2017. Federal health advisers are considering the first request to approve the mind-altering club drug MDMA as a treatment for PTSD. The advisers to the Food and Drug Administration are scheduled to vote on the drug’s safety and effectiveness Tuesday, June 4, 2024, potentially setting the stage for federal approval later this year. Credit: AP Photo/Robert F. Bukaty, File Federal health advisers are weighing Read More

Related posts:

  1. Magic mushrooms are the most-used psychedelic drug
  2. Illegal ecstasy takes step toward becoming legal drug for PTSD
  3. New medication for stress urinary incontinence? Investigational drug shows promise
  4. New MDMA variants identified for potentially safer psychotherapeutic use
  5. FDA panel OKs new COVID vaccine for fall
  6. Expert panel develops new definition of long COVID
  7. Ketamine pill treats depression without psychedelic effects: study
  8. Canada faces scourge of rising car thefts

Leave a Reply

Your email address will not be published. Required fields are marked *